Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1701963 +/- BI 3011441 in KRAS Mutated Solid Tumors
NCT04835714Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1701963 in solid tumor (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-Limiting Toxicities at 28 days and Objective Response at 12 months. Started Apr 2021; status: terminated.
02
Drugs
BI 1701963
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04835714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835714.